When was XCath founded?

XCath was founded in 2017 and raised its 1st funding round 9 years after it was founded.

Where is XCath located?

XCath is headquartered in Houston, United States.

How many employees does XCath have?

As of Jun 30, 2026, the latest employee count at XCath is 37.

Is XCath a funded company?

XCath is a funded company, having raised a total of $***** in its 1st and only funding round, a Series C round on Mar 12, 2026.

How much is XCath worth?

The latest valuation of XCath is $***** as of Dec 05, 2025.

When was the latest funding round of XCath?

XCath's latest funding was a $***** Series C round on Mar 12, 2026, with participation from 2 investors. Its primary sector is Neurology. In United States, the Neurology sector has seen $3.1B in funding in 2026 to date.

Where does XCath rank among its competitors?

XCath ranks 4th amongst 54 active competitors, of which 19 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was XCath, which secured $30M in Mar, 2026.

Who are the top competitors of XCath?

XCath's top competitors include Rapid Medical, Penumbra and Cerevast. Among them, XCath secured the most recent funding round in March, 2026.

XCath - 2026 Company Profile, Team, Funding & Competitors

XCath is a series C company based in Houston (United States), founded in 2017. It operates as a Developer of endovascular robotics and steerable guidewires. XCath has raised $92M in funding from Crescent Enterprises, with a current valuation of $*****. The company has 54 active competitors, including 19 funded and 15 that have exited. Its top competitors include companies like Rapid Medical, Penumbra and Cerevast.

Company Details

Developer of endovascular robotics and steerable guidewires. The company is developing robotic systems that can enable expert navigation of the body's complex vascular network to treat life-threatening conditions like cerebrovascular disorders.

Website: xcath.com
Email ID: *****@xcath.com

Key Metrics

Founded Year

2017

Location

Houston, United States

Stage

Series C

Total Funding

$92M in 1 round

Latest Funding Round

Series C, Mar 12, 2026, $*****

Post Money Valuation

$***** as on Dec 05, 2025

Investors

Crescent Enterprises & 1 more

Ranked

4^th among 54 active competitors

Employee Count

37 as on Jun 30, 2026

Similar Companies

Terumo Neuro & 18 more

View XCath's full profile

XCath is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
XCATH INC CIN: 813485360 , United States, Active	Dec 31, 1999	-	17 (As on Dec 31, 2024)	-

XCath has raised a total funding of $92M over 1 round. Its latest funding round was a Series C round on Mar 12, 2026 for $*****. 2 investors participated in its latest round. XCath has 1 institutional investor and 1 angel investor.

Here is the list of recent funding rounds of XCath:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 12, 2026	5740449	Series C	2618993	7293463	6620316	9943774

Access funding benchmarks and valuations. Sign up today!

View details of XCath's funding rounds and investors

XCath's employee count trend

XCath has 37 employees as of Jun 26. Here is XCath's employee count trend over the years:

Uncover XCath's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of XCath include Rapid Medical, Penumbra and Cerevast. Here is the list of Top 10 competitors of XCath, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Rapid Medical 2008, Yokneam Illit (Israel), Series D	Developer of neurovascular interventional devices such as distal access & microcatheters	$79M	MicroPort Orthopedics, BRM & 9 others	64/100
2nd	Penumbra 2004, Alameda (United States), Acquired	Developer of medical devices for neurovascular and peripheral thrombectomy	$121K	Novo Holdings, The Angels’ Forum & 4 others	63/100
3rd	Cerevast 2009, Bothell (United States), Series C	Medical device company developing innovative ultrasound and microsphere therapies	$46.9M	Swiftsure, Haiyin Capital	50/100
4th	XCath 2017, Houston (United States), Series C	Developer of endovascular robotics and steerable guidewires	$92M	Crescent Enterprises & 1 others	49/100
5th	Sequent Medical 2007, Aliso Viejo (United States), Acquired	Catheter-based neurovascular devices	$65.3M	Delphi Ventures, Domain Associates & 4 others	48/100
6th	Terumo Neuro 1997, Aliso Viejo (United States), Unfunded	Developer of minimally-invasive devices for the treatment of vascular diseases in the brain	-	-	46/100
7th	MicroVention 1997, Tustin (United States), Acquired	Innovative neurovascular solutions for hemorrhagic and ischemic stroke treatment	-	Domain Associates, Advanced Technology Ventures ... & 4 others	45/100
8th	BrainsGate 2000, Caesarea (Israel), Series F	Electrical stimulation therapy for CNS diseases	$97M	BNP Paribas, Medtronic & 11 others	44/100
9th	Anaconda Biomed 2015, Barcelona (Spain), Series B	Developer of medical devices for mechanical thromboectomy procedures	$39M	Omega Funds, Ysios Capital & 6 others	44/100
10th	Galaxy Therapeutics 2012, Milpitas (United States), Funding Raised	Developer of neurovascular devices to treat brain aneurysms	-	National Science Foundation	44/100